Zhou 2010.

Study name	b‐PRESERVE
Methods	Study design: "multicentre, prospective, randomized, open‐label, blinded endpoint trial" Anticipated completion date:
Participants	Estimated enrolment: "A total of 1200 patients will be randomized to either b‐blocker (metoprolol succinate) or control (n = 600 per group)." Inclusion criteria: "The most essential criteria for HFNEF in this trial are: heart failure symptoms, elevated NT‐proBNP 1500 pg/mL, and LVEF 50%. In addition, age.40 years and a recent hospitalization for heart failure, but not within 3 months prior to enrolment, are required." Exclusion criteria:
Interventions	"The follow‐up period is a minimum of 2 years."
Outcomes	"The primary endpoint is a composite of hospitalization for heart failure and cardiovascular death. The secondary endpoints include cardiovascular death, heart failure mortality or hospitalization, all‐cause mortality, change in New York Heart Association class, change in left ventricular ejection fraction, increase in NT‐proBNP (by 50% of the value at randomization), b‐blocker tolerance, and premature termination of b‐blocker therapy due to adverse events"
Starting date	not reported
Contact information	Email: ge.junbo@zs‐hospital.sh.cn or jbge@zs‐hospital.sh.cn
Notes	Could not find the entry in the Chinese Clinical Trial Register with ID ChiCTR‐TNC‐00000144. Contacted investigators to clarify status of study. No response.

ACEI: angiotensin‐converting‐enzyme inhibitor

ARB: angiotensin II receptor blockers

CMR: cardiac magnetic resonance

ECV: extra‐cellular volume

HTN: hypertension

KCCQ: Kansas City Cardiomyopathy Questionnaire

LVEF: left ventricular ejection fraction

NYHA: New York Heart Association Classification of heart failure

QoL: quality of life

RCT: randomised controlled trial